This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Procalcitonin Guided Antibiotic Use in Acute Respiratory Tract Infections (PARTI)-Study

This study has been completed.
Basel Institute of Clinical Epidemiology (BICE)
Brahms AG
Information provided by:
University Hospital, Basel, Switzerland Identifier:
First received: December 21, 2004
Last updated: April 24, 2007
Last verified: January 2006

Acute respiratory tract infections (ARTI) are among the most frequent reasons for seeking medical attention in primary care. Although from predominantly viral origin, ARTIs are the most important condition for the prescription of antibiotics (AB), mainly due to the difficulty in primary care to differentiate between viral and bacterial etiology. Unnecessary AB use increases drug expenditures, side effects and AB resistance. A novel approach is to guide AB use by procalcitonin (ProCT), since serum levels are elevated in bacterial infections but remain lower in viral infections and inflammatory diseases.

We aim to compare a strategy based on evidence-based guidelines with ProCT guided AB therapy in ARTIs with respect to outcome (days with restriction) and AB use. Patients presenting with ARTIs to primary care physicians and are intended to be treated with AB based on guidelines will be included and randomized 1:1 either to standard management or to the ProCT guided prescription of AB. All participating physicians will receive evidence-based guidelines for the management of patients with ARTIs. Patients with ARTI and in need of ABs by physicians’ clinical judgment and with informed consent will be randomized to ProCT plus guidelines ("ProCT group") versus only guidelines guided AB treatment ("control group"). In patients randomized to the ProCT group, the use of antibiotics will be more or less discouraged (<0.1 or <0.25 ug/L) or encouraged (>0.5 or >0.25 ug/L), respectively. A re-evaluation in patients with ProCT (<0.1 or <0.25 ug/L) after 6 to 24 hours is mandatory. All patients will be reassessed at day 3 and it is recommended to stop AB in the ProCT group as described above. Structured phone interviews at days 14 and 28 will be done in all patients from both groups.

Condition Intervention
Respiratory Tract Infections Procedure: Procalcitonin guided antibiotic therapy

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Procalcitonin Guided Antibiotic Use in Acute Respiratory Tract Infections in Primary Care - A Randomized Controlled Trial

Resource links provided by NLM:

Further study details as provided by University Hospital, Basel, Switzerland:

Primary Outcome Measures:
  • Days with restrictions from ARTI

Secondary Outcome Measures:
  • Rate of AB prescriptions
  • days with AB use
  • symptoms from ARTI
  • relapse rate from ARTI within 28 days
  • days with side effects from ABs and off work
  • cost-effectiveness

Estimated Enrollment: 400
Study Start Date: December 2004
Study Completion Date: April 2006
  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years or older
  • ARTI of >1 and <28 days duration
  • In need of ABs based on the clinical judgment of the primary care physician

Exclusion Criteria:

  • Patients without informed consent
  • Not fluent in German
  • AB pretreatment in previous 28 days
  • Severe immune-suppression
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00099840

University Hospital
Basel, CH, Switzerland, 4031
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Basel Institute of Clinical Epidemiology (BICE)
Brahms AG
Study Chair: Beat Muller, MD University Hospital, Basel, Switzerland
  More Information

Publications: Identifier: NCT00099840     History of Changes
Other Study ID Numbers: PARTIS
Study First Received: December 21, 2004
Last Updated: April 24, 2007

Keywords provided by University Hospital, Basel, Switzerland:
common cold
otitis media
acute exacerbations of asthma
acute exacerbations of chronic pulmonary disease
community acquired pneumonia

Additional relevant MeSH terms:
Communicable Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Anti-Bacterial Agents
Antibiotics, Antitubercular
Anti-Infective Agents
Antitubercular Agents processed this record on September 19, 2017